2020
TAMI-54. THE PRESENCE OF IMMUNE CELL INFILTRATES IN THE TISSUE MICROENVIRONMENT OF HIGH-GRADE GLIOMAS AND THEIR ASSOCIATION WITH OVERALL SURVIVAL
Rishi A, Mohammadi H, Martir D, Welsh E, Robinson T, Oliver D, Eschrich S, Torres-Roca J, Yu H, Grass G, Ahmed K. TAMI-54. THE PRESENCE OF IMMUNE CELL INFILTRATES IN THE TISSUE MICROENVIRONMENT OF HIGH-GRADE GLIOMAS AND THEIR ASSOCIATION WITH OVERALL SURVIVAL. Neuro-Oncology 2020, 22: ii225-ii225. PMCID: PMC7651565, DOI: 10.1093/neuonc/noaa215.941.Peer-Reviewed Original ResearchImmune cell infiltratesHigh-grade gliomasPrimary surgical resectionOverall survivalICI subtypesSurgical resectionCell infiltratePrimary high-grade gliomasActuarial OS ratesTumor associated microgliaGrade 4 tumorsKaplan-Meier estimatesLog-rank testBrain tumor biologyPotential therapeutic targetM2-polarized macrophagesMost patientsVs. 11Median ageOS ratesTumor characteristicsCox regressionM2-TAMsM2 macrophagesVs. 31
2019
ATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMAS
Sahebjam S, Forsyth P, Tran N, Etame A, Arrington J, Jaglal M, Mokhtari S, MacAulay R, Wicklund M, Evernden B, Gatewood T, Robinson T, Raval R, Yu M. ATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMAS. Neuro-Oncology 2019, 21: vi5-vi5. PMCID: PMC6847102, DOI: 10.1093/neuonc/noz175.017.Peer-Reviewed Original ResearchGrade 1 elevationExpansion cohortSafety cohortPD-1/PDLStrong pre-clinical evidencesAnti-tumor immune responseRecurrent high-grade gliomaPhase IDose-expansion cohortsGrade 1 anorexiaGrade 1 diarrheaRT treatment fieldUse of corticosteroidsPre-clinical evidenceHigh-grade gliomasPrimary study objectiveCommon toxicitiesEligible ptsPrior RTSecondary endpointsFlat doseRecurrent tumorsGrade IIITumor regressionEfficacy data
2017
Nivolumab combined with hypofractionated stereotactic irradiation (HFSRT) for patients with recurrent high grade gliomas: A phase I trial (NCT02829931).
Sahebjam S, Forsyth P, Arrington J, Tran N, Jaglal M, Mokhtari S, Long W, Macaulay R, Wicklund M, Drury-Sibiga A, Gatewood T, Robinson T, Raval R, Yu M. Nivolumab combined with hypofractionated stereotactic irradiation (HFSRT) for patients with recurrent high grade gliomas: A phase I trial (NCT02829931). Journal Of Clinical Oncology 2017, 35: tps2084-tps2084. DOI: 10.1200/jco.2017.35.15_suppl.tps2084.Peer-Reviewed Original ResearchHigh-grade gliomasPhase I trialGrade gliomasI trialPD-1PD-L1Grade IIIAnti-PD-1/PD-L1 blockadePD-1/PD-L1 blockadeRecurrent high-grade gliomaOngoing phase I trialDose-expansion cohortsPD-L1 blockadePrior radiation therapyTolerability of nivolumabGroup of patientsImmune checkpoint pathwaysLimited treatment optionsPreliminary antitumor activityOrthotopic murine modelLong-term survivalPrimary study objectiveIgG4 monoclonal antibodyNivolumab monotherapySafety cohort